Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus

被引:10
作者
Bernabeu, Ignacio [1 ]
Aller, Javier [2 ]
Alvarez-Escola, Cristina [3 ]
Fajardo-Montanana, Carmen [4 ]
Galvez-Moreno, Angeles [5 ]
Guillin-Amarelle, Cristina [6 ]
Sesmilo, Gemma [7 ]
机构
[1] Univ Santiago Compostela, Complejo Hosp, Serv Endocrinol & Nutr, La Coruna, Spain
[2] Hosp Univ Puerta Hierro Majadahonda, Serv Endocrinol & Nutr, Madrid, Spain
[3] Hosp Univ La Paz, Serv Endocrinol & Nutr, Madrid, Spain
[4] Hosp Univ La Ribera, Serv Endocrinol & Nutr, Valencia, Spain
[5] Hosp Univ Reina Sofia, Serv Endocrinol & Nutr, Cordoba, Spain
[6] Univ Ourense, Complejo Hosp, Serv Endocrinol & Nutr, Orense, Spain
[7] Hosp Univ Dexeus, Serv Endocrinol & Nutr, Barcelona, Spain
来源
ENDOCRINOLOGIA DIABETES Y NUTRICION | 2018年 / 65卷 / 05期
关键词
Acromegaly; Comorbidity; Diagnosis; Management; Screening; Diabetes; GLUCOSE-HOMEOSTASIS; THYROID-CANCER; FOLLOW-UP; MORTALITY; RISK; EPIDEMIOLOGY; METAANALYSIS; PEGVISOMANT; PASIREOTIDE; OCTREOTIDE;
D O I
10.1016/j.endinu.2018.01.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Acromegaly is a rare disease with many comorbidities that impair quality of life and limit survival. There are discrepancies in various clinical guidelines regarding diagnosis and postoperative control criteria, as well as screening and optimal management of comorbidities. This expert consensus was aimed at establishing specific recommendations for the Spanish healthcare system. The existing recommendations, the scientific evidence on which they are based, and the main controversies are reviewed. Unfortunately, the low prevalence and high clinical variability of acromegaly do not provide strong scientific evidences. To mitigate this disadvantage, a modified Delphi questionnaire, combining the best available scientific evidence with the collective judgment of experts, was used. The questionnaire, generated after a face-to-face debate, was completed by 17 Spanish endocrinologists expert in acromegaly. A high degree of consensus was reached (79.3%), as 65 of the total 82 statements raised were accepted. Some criteria for diagnosis and postoperative control were identified by this procedure. Regarding comorbidities, recommendations have been established or suggested for screening and management of oncological, cardiovascular, respiratory (sleep apnea), metabolic (dystipidemia and diabetes), musculoskeletal, and hypopituitarism-related disorders. Consensus recommendations may facilitate and homogenize clinical care to patients with acromegaly in the Spanish health system. (C) 2018 SEEN y SED. Published by Elsevier Espana, S.L.U. All rights reserved.
引用
收藏
页码:297 / 305
页数:9
相关论文
共 32 条
[1]   Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant [J].
Barkan, AL ;
Burman, P ;
Clemmons, DR ;
Drake, WM ;
Gagel, RF ;
Harris, PE ;
Trainer, PJ ;
van der Lely, AJ ;
Vance, ML .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (10) :5684-5691
[2]   Acromegaly and cancer: an old debate revisited [J].
Boguszewski, Cesar Luiz ;
Ayuk, John .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2016, 175 (04) :R147-R156
[3]   Management of hyperglycemia associated with pasireotide (SOM230): Healthy volunteer study [J].
Breitschaft, Astrid ;
Hu, Ke ;
Resendiz, Karina Hermosillo ;
Darstein, Christelle ;
Golor, Georg .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 103 (03) :458-465
[4]   The Role of Diabetes in Acromegaly Associated Neoplasia [J].
Cheng, Sonia ;
Gomez, Karen ;
Serri, Omar ;
Chik, Constance ;
Ezzat, Shereen .
PLOS ONE, 2015, 10 (05)
[5]   Bone and Joint Disorders in Acromegaly [J].
Claessen, Kim M. J. A. ;
Mazziotti, Gherardo ;
Biermasz, Nienke R. ;
Giustina, Andrea .
NEUROENDOCRINOLOGY, 2016, 103 (01) :86-95
[6]   Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study [J].
Colao, A. ;
Bronstein, M. D. ;
Freda, P. ;
Gu, F. ;
Shen, C. -C. ;
Gadelha, M. ;
Fleseriu, M. ;
van der Lely, A. J. ;
Farrall, A. J. ;
Resendiz, K. Hermosillo ;
Ruffin, M. ;
Chen, Y. ;
Sheppard, M. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (03) :791-799
[7]   Systemic complications of acromegaly: Epidemiology, pathogenesis, and management [J].
Colao, A ;
Ferone, D ;
Marzullo, P ;
Lombardi, G .
ENDOCRINE REVIEWS, 2004, 25 (01) :102-152
[8]  
Cordido F, 2013, ENDOCRINOL NUTR, V60, DOI 10.1016/j.endonu.2013.01.012
[9]   Increased thyroid cancer risk in acromegaly [J].
Dagdelen, Selcuk ;
Cinar, Nese ;
Erbas, Tomris .
PITUITARY, 2014, 17 (04) :299-306
[10]   Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels [J].
Droste, Michael ;
Domberg, Julia ;
Buchfelder, Michael ;
Mann, Klaus ;
Schwanke, Anja ;
Stalla, Guenter ;
Strasburger, Christian J. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2014, 171 (01) :59-68